Peritoneal mesothelioma: treatment approach based on natural history.

Cancer Treat Res

Cancer Institute, Washington Hospital Center, DC 20010, USA.

Published: December 1996

A more modern treatment strategy for diffuse malignant peritoneal mesothelioma may be suggested (figure 3). Clinical suspicion of diffuse malignant mesothelioma (peritoneal carcinomatosis) calls for laparoscopy with evaluation of parietal and visceral peritoneum and multiple biopsies sufficient for definitive histologic diagnosis. Cytologic examination of ascitic fluid is not likely to be of benefit. CT of chest, abdomen, and pelvis is needed for evaluation of visceral involvement and the presence of distant metastases. Contrast enhancement of the gastrointestinal and urinary tract is necessary with the CT. Additional radiologic techniques for detection of distant metastases should be used if there are clinical or laboratory signs of extraperitoneal spread. After histologic diagnosis and extent of tumor spread have been documented, and if no symptoms of intestinal obstruction are present, the patient may be subjected to two to three courses of induction intraperitoneal chemotherapy. This will provide the clinician with important information on tumor response to chemotherapy, minimize tumor accumulation on bowel surfaces, and provide time for surgical conditioning. The time devoted to induction chemotherapy will allow occult distant metastases to be detected. In patients with a response or stable disease, cytoreductive surgery is attempted approximately 2 months after completion of induction chemotherapy. Surgery must be aimed at achieving complete or near-complete cytoreduction through the use of peritonectomy procedures [46,47]. Additional intraperitoneal chemotherapy should be administered intraoperatively and in the early postoperative period (figure 3). This treatment strategy may be the most feasible one according to existing knowledge of the natural history of diffuse malignant peritoneal mesothelioma. Only further phase II clinical trials can reveal the extent to which it is beneficial. Because of the rare occurrence of this disease, the quickest answer would come as a result of cooperative study by several groups experienced in these treatment modalities.

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4613-1245-1_17DOI Listing

Publication Analysis

Top Keywords

peritoneal mesothelioma
12
diffuse malignant
12
distant metastases
12
natural history
8
treatment strategy
8
malignant peritoneal
8
histologic diagnosis
8
intraperitoneal chemotherapy
8
chemotherapy will
8
induction chemotherapy
8

Similar Publications

Background/objectives: Telomerase reverse transcriptase (TERT) is the catalytic subunit of the telomerase enzyme responsible for telomere length maintenance and is an important cancer hallmark. Our study aimed to clarify the mRNA expression of TERT in peritoneal mesothelioma (PeM), and to explore the relationship between its expression and the clinicopathological parameters and prognosis of patients with PeM.

Methods: In a cohort of 13 MpeM patients, we evaluated histotype, nuclear grade, mitotic count, necrosis, inflammation, Ki67, BAP1, MTAP and p16 expression by immunohistochemistry, / status by FISH and TERT mRNA expression by RNAscope.

View Article and Find Full Text PDF

A Rare Case of Peritoneal Mesothelioma Detected by 18F-AlF-NOTA-Octreotide PET/CT.

Clin Nucl Med

January 2025

From the Department of Nuclear Medicine (PET-CT Center), National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

We present a case of 37-year-old man with multiple masses in the abdominal and pelvic cavity who underwent 18F-AlF-NOTA-octreotide PET/CT. The masses demonstrated heterogeneously increased uptake on 18F-AlF-NOTA-octreotide PET/CT and were suggestive of neuroendocrine tumor. However, the histopathological examinations confirmed the masses to be peritoneal mesothelioma.

View Article and Find Full Text PDF

68Ga-FAPI PET/CT Depicted Non-FDG-Avid Malignant Peritoneal Mesothelioma.

Clin Nucl Med

January 2025

Department of Ultrasound, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, China.

Malignant peritoneal mesothelioma (MPM) is a rare and aggressive malignancy of mesothelial cells in the peritoneum. Herein, we describe the 68Ga-FAPI and 18F-FDG PET/CT findings of MPM in a 41-year-old man. In the present case, the primary and metastatic tumors showed intense 68Ga-FAPI accumulation but no significantly increased 18F-FDG uptake.

View Article and Find Full Text PDF

Background: Hematologic changes after splenectomy and hyperthermic intraperitoneal chemotherapy (HIPEC) can complicate postoperative assessment of infection. This study aimed to develop a machine-learning model to predict postoperative infection after cytoreductive surgery (CRS) and HIPEC with splenectomy.

Methods: The study enrolled patients in the national TriNetX database and at the Johns Hopkins Hospital (JHH) who underwent splenectomy during CRS/HIPEC from 2010 to 2024.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!